Dysregulation of RIPK3 has been frequently observed in tumor cells, including those from colorectal, breast, and lung cancers, contributing to impaired necroptotic signaling and enhanced tumor survival [57, 58, 59]. This evidence concerns the gene RIPK3 and neoplasm.